title: Isradipine: a slow-release formulation given once daily controls blood pressure for 24 h.
abstract: A total of 190 patients (mean age 57 years; range 21 to 89 years), with a supine diastolic blood pressure (sDBP) of 100 to 120 mm Hg after a 3-week placebo phase, entered a double-blind parallel-group study to receive placebo (n = 62), or slow-release isradipine (SRO) at 2.5 mg (n = 64) or 5 mg (n = 64) once daily for 4 weeks. Blood pressure was always measured between 23.5 and 24.5 h after the previous drug administration. Before and after the 4-week treatment period, blood pressure profiles were recorded from measurements taken immediately before drug administration ('trough') and repeated at 2, 4, 6, and 8 h after administration. A 'peak:trough' ratio was assessed from the data of 156 patients who completed the 4 weeks of active treatment, and for whom blood pressure profiles were available both before and after treatment. A supine DBP of < or = 90 mm Hg at trough was achieved by 28%, 35%, and 47% of patients receiving placebo, 2.5 mg, and 5 mg SRO, respectively. If patients who achieved a reduction in sDBP of at least 10 mm Hg are included, the total response rate becomes 42%, 66%, and 61% in the three treatment groups, respectively. The reduction in sDBP immediately before drug administration (trough effect) was 37% of the 'peak' effect (6 h after administration) with the 2.5-mg dose and 74% with the 5-mg dose. Adverse events were reported by 14.5%, 9.4%, and 17.2% of patients taking placebo and SRO at 2.5 mg and 5 mg, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
authors: Department of Clinical Research, Sandoz Pharma Ltd., Basel, Switzerland.
authors: D G
authors: DG
authors: Holmes
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001794:Blood Pressure / Q000187:drug effects; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D017275:Isradipine / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D003692:Delayed-Action Preparations; D017275:Isradipine